Skip to main content
. 2021 Oct 4;7(10):e08124. doi: 10.1016/j.heliyon.2021.e08124

Figure 4.

Figure 4

IFN-γ responses in convalescent patients. A) Immunoblot analysis of five different batches of PRAK-03202 (PR-01 to PR-05) when probed with sera from convalescent patients. M = marker, PR-01-PR-05: 5 batches of PRAK-03202 (Refer: Supplementary Figure 2A). B) Immunoblot analysis of PRAK-03202 when probed with sera from four convalescent patients (PR-S1 to PR-S4) (Refer: Supplementary Figure 2B). C) Lymphocyte proliferation in PRAK-03202 (2.5 μg and 5 μg)-stimulated PBMCs from controls (n = 2) and convalescent COVID-19 patients (n = 5). Samples were stimulated for 120 h, and the BrDU assay was performed (Cell Proliferation ELISA BrDU, Roche, USA). The plates were read at 450/690 nm using an ELISA plate reader. OD values represent means ± SEM. Significant differences between controls and patients were observed. ∗Indicates a statistically significant difference (p < 0.05). D) Cytokine staining for IFN-γ by ELISA in controls and convalescent patient samples stimulated with two different doses (2.5 μg and 5 μg) of PRAK-03202. Error bars indicate SEM.